PortalPublikationenOutcomes After Current Transcatheter Tricuspid Valve Interve...

Outcomes After Current Transcatheter Tricuspid Valve Intervention: Mid-Term Results From the International TriValve Registry

Standard

Outcomes After Current Transcatheter Tricuspid Valve Intervention: Mid-Term Results From the International TriValve Registry. / Taramasso, Maurizio; Alessandrini, Hannes; Latib, Azeem; Asami, Masahiko; Attinger-Toller, Adrian; Biasco, Luigi; Braun, Daniel; Brochet, Eric; Connelly, Kim A; Denti, Paolo; Deuschl, Florian; Englmeier, Andrea; Fam, Neil; Frerker, Christian; Hausleiter, Jörg; Himbert, Dominique; Ho, Edwin C; Juliard, Jean-Michel; Kaple, Ryan; Kreidel, Felix; Kuck, Karl-Heinz; Ancona, Marco; Lauten, Alexander; Lurz, Philipp; Mehr, Michael; Nazif, Tamin; Nickening, Georg; Pedrazzini, Giovanni; Pozzoli, Alberto; Praz, Fabien; Puri, Rishi; Rodés-Cabau, Josep; Schäfer, Ulrich; Schofer, Joachim; Sievert, Horst; Sievert, Kolja; Tang, Gilbert H L; Tanner, Felix C; Vahanian, Alec; Webb, John G; Windecker, Stephan; Yzeiray, Ermela; Zuber, Michel; Maisano, Francesco; Leon, Martin B; Hahn, Rebecca T.

in: JACC-CARDIOVASC INTE, Jahrgang 12, Nr. 2, 28.01.2019, S. 155-165.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Taramasso, M, Alessandrini, H, Latib, A, Asami, M, Attinger-Toller, A, Biasco, L, Braun, D, Brochet, E, Connelly, KA, Denti, P, Deuschl, F, Englmeier, A, Fam, N, Frerker, C, Hausleiter, J, Himbert, D, Ho, EC, Juliard, J-M, Kaple, R, Kreidel, F, Kuck, K-H, Ancona, M, Lauten, A, Lurz, P, Mehr, M, Nazif, T, Nickening, G, Pedrazzini, G, Pozzoli, A, Praz, F, Puri, R, Rodés-Cabau, J, Schäfer, U, Schofer, J, Sievert, H, Sievert, K, Tang, GHL, Tanner, FC, Vahanian, A, Webb, JG, Windecker, S, Yzeiray, E, Zuber, M, Maisano, F, Leon, MB & Hahn, RT 2019, 'Outcomes After Current Transcatheter Tricuspid Valve Intervention: Mid-Term Results From the International TriValve Registry', JACC-CARDIOVASC INTE, Jg. 12, Nr. 2, S. 155-165. https://doi.org/10.1016/j.jcin.2018.10.022

APA

Taramasso, M., Alessandrini, H., Latib, A., Asami, M., Attinger-Toller, A., Biasco, L., Braun, D., Brochet, E., Connelly, K. A., Denti, P., Deuschl, F., Englmeier, A., Fam, N., Frerker, C., Hausleiter, J., Himbert, D., Ho, E. C., Juliard, J-M., Kaple, R., ... Hahn, R. T. (2019). Outcomes After Current Transcatheter Tricuspid Valve Intervention: Mid-Term Results From the International TriValve Registry. JACC-CARDIOVASC INTE, 12(2), 155-165. https://doi.org/10.1016/j.jcin.2018.10.022

Vancouver

Taramasso M, Alessandrini H, Latib A, Asami M, Attinger-Toller A, Biasco L et al. Outcomes After Current Transcatheter Tricuspid Valve Intervention: Mid-Term Results From the International TriValve Registry. JACC-CARDIOVASC INTE. 2019 Jan 28;12(2):155-165. https://doi.org/10.1016/j.jcin.2018.10.022

Bibtex

@article{3ad9e6a13a484d7e910f19bac2aee089,
title = "Outcomes After Current Transcatheter Tricuspid Valve Intervention: Mid-Term Results From the International TriValve Registry",
abstract = "OBJECTIVES: A large, prospective international registry was developed to evaluate the initial clinical applications of transcatheter tricuspid valve intervention (TTVI) with different devices.BACKGROUND: TTVI for native tricuspid valve dysfunction has been emerging during the last few years as an alternative therapeutic option to serve a large high-risk population of patients with severe symptomatic tricuspid regurgitation (TR).METHODS: The TriValve Registry included 312 high-risk patients with severe TR (76.4 ± 8.5 years of age; 57% female; EuroSCORE II 9 ± 8%) at 18 centers. Interventions included repair at the level of the leaflets (MitraClip, Abbott Vascular, Santa Clara, California; PASCAL Edwards Lifesciences, Irvine, California), annulus (Cardioband, Edwards Lifesciences; TriCinch, 4tech, Galway, Ireland; Trialign, Mitraling, Tewksbury, Massachusetts), or coaptation (FORMA, Edwards Lifesciences) and replacement (Caval Implants, NaviGate, NaviGate Cardiac Structures, Lake Forest, California). Clinical outcomes were prospectively determined during mid-term follow-up.RESULTS: A total of 108 patients (34.6%) had prior left heart valve intervention (84 surgical and 24 transcatheter, respectively). TR etiology was functional in 93%, and mean annular diameter was 46.9 ± 9 mm. In 75% of patients the regurgitant jet was central (vena contracta 1.1 ± 0.5; effective regurgitant orifice area 0.78 ± 0.6 cm2). Pre-procedural systolic pulmonary artery pressure was 41 ± 14.8 mm Hg. Implanted devices included: MitraClip in 210 cases, Trialign in 18 cases, TriCinch first generation in 14 cases, caval valve implantation in 30 cases, FORMA in 24 cases, Cardioband in 13 cases, NaviGate in 6 cases, and PASCAL in 1. In 64% of the cases, TTVI was performed as a stand-alone procedure. Procedural success (defined as the device successfully implanted and residual TR ≤2+) was 72.8%. Greater coaptation depth (odds ratio: 24.1; p = 0.002) was an independent predictor of reduced device success. Thirty-day mortality was 3.6% and was significantly lower among patients with procedural success (1.9% vs. 6.9%; p = 0.04); Actuarial survival at 1.5 years was 82.8 ± 4% and was significantly higher among patients who had procedural success achieved.CONCLUSIONS: TTVI is feasible with different technologies, has a reasonable overall procedural success rate, and is associated with low mortality and significant clinical improvement. Mid-term survival is favorable in this high-risk population. Greater coaptation depth is associated with reduced procedural success, which is an independent predictor of mortality.",
keywords = "Aged, Aged, 80 and over, Cardiac Catheterization/adverse effects, Europe, Female, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation/adverse effects, Humans, Male, North America, Prospective Studies, Prosthesis Design, Recovery of Function, Registries, Severity of Illness Index, Time Factors, Treatment Outcome, Tricuspid Valve/diagnostic imaging, Tricuspid Valve Insufficiency/diagnostic imaging",
author = "Maurizio Taramasso and Hannes Alessandrini and Azeem Latib and Masahiko Asami and Adrian Attinger-Toller and Luigi Biasco and Daniel Braun and Eric Brochet and Connelly, {Kim A} and Paolo Denti and Florian Deuschl and Andrea Englmeier and Neil Fam and Christian Frerker and J{\"o}rg Hausleiter and Dominique Himbert and Ho, {Edwin C} and Jean-Michel Juliard and Ryan Kaple and Felix Kreidel and Karl-Heinz Kuck and Marco Ancona and Alexander Lauten and Philipp Lurz and Michael Mehr and Tamin Nazif and Georg Nickening and Giovanni Pedrazzini and Alberto Pozzoli and Fabien Praz and Rishi Puri and Josep Rod{\'e}s-Cabau and Ulrich Sch{\"a}fer and Joachim Schofer and Horst Sievert and Kolja Sievert and Tang, {Gilbert H L} and Tanner, {Felix C} and Alec Vahanian and Webb, {John G} and Stephan Windecker and Ermela Yzeiray and Michel Zuber and Francesco Maisano and Leon, {Martin B} and Hahn, {Rebecca T}",
note = "Copyright {\textcopyright} 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.",
year = "2019",
month = jan,
day = "28",
doi = "10.1016/j.jcin.2018.10.022",
language = "English",
volume = "12",
pages = "155--165",
journal = "JACC-CARDIOVASC INTE",
issn = "1936-8798",
publisher = "Elsevier Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Outcomes After Current Transcatheter Tricuspid Valve Intervention: Mid-Term Results From the International TriValve Registry

AU - Taramasso, Maurizio

AU - Alessandrini, Hannes

AU - Latib, Azeem

AU - Asami, Masahiko

AU - Attinger-Toller, Adrian

AU - Biasco, Luigi

AU - Braun, Daniel

AU - Brochet, Eric

AU - Connelly, Kim A

AU - Denti, Paolo

AU - Deuschl, Florian

AU - Englmeier, Andrea

AU - Fam, Neil

AU - Frerker, Christian

AU - Hausleiter, Jörg

AU - Himbert, Dominique

AU - Ho, Edwin C

AU - Juliard, Jean-Michel

AU - Kaple, Ryan

AU - Kreidel, Felix

AU - Kuck, Karl-Heinz

AU - Ancona, Marco

AU - Lauten, Alexander

AU - Lurz, Philipp

AU - Mehr, Michael

AU - Nazif, Tamin

AU - Nickening, Georg

AU - Pedrazzini, Giovanni

AU - Pozzoli, Alberto

AU - Praz, Fabien

AU - Puri, Rishi

AU - Rodés-Cabau, Josep

AU - Schäfer, Ulrich

AU - Schofer, Joachim

AU - Sievert, Horst

AU - Sievert, Kolja

AU - Tang, Gilbert H L

AU - Tanner, Felix C

AU - Vahanian, Alec

AU - Webb, John G

AU - Windecker, Stephan

AU - Yzeiray, Ermela

AU - Zuber, Michel

AU - Maisano, Francesco

AU - Leon, Martin B

AU - Hahn, Rebecca T

N1 - Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

PY - 2019/1/28

Y1 - 2019/1/28

N2 - OBJECTIVES: A large, prospective international registry was developed to evaluate the initial clinical applications of transcatheter tricuspid valve intervention (TTVI) with different devices.BACKGROUND: TTVI for native tricuspid valve dysfunction has been emerging during the last few years as an alternative therapeutic option to serve a large high-risk population of patients with severe symptomatic tricuspid regurgitation (TR).METHODS: The TriValve Registry included 312 high-risk patients with severe TR (76.4 ± 8.5 years of age; 57% female; EuroSCORE II 9 ± 8%) at 18 centers. Interventions included repair at the level of the leaflets (MitraClip, Abbott Vascular, Santa Clara, California; PASCAL Edwards Lifesciences, Irvine, California), annulus (Cardioband, Edwards Lifesciences; TriCinch, 4tech, Galway, Ireland; Trialign, Mitraling, Tewksbury, Massachusetts), or coaptation (FORMA, Edwards Lifesciences) and replacement (Caval Implants, NaviGate, NaviGate Cardiac Structures, Lake Forest, California). Clinical outcomes were prospectively determined during mid-term follow-up.RESULTS: A total of 108 patients (34.6%) had prior left heart valve intervention (84 surgical and 24 transcatheter, respectively). TR etiology was functional in 93%, and mean annular diameter was 46.9 ± 9 mm. In 75% of patients the regurgitant jet was central (vena contracta 1.1 ± 0.5; effective regurgitant orifice area 0.78 ± 0.6 cm2). Pre-procedural systolic pulmonary artery pressure was 41 ± 14.8 mm Hg. Implanted devices included: MitraClip in 210 cases, Trialign in 18 cases, TriCinch first generation in 14 cases, caval valve implantation in 30 cases, FORMA in 24 cases, Cardioband in 13 cases, NaviGate in 6 cases, and PASCAL in 1. In 64% of the cases, TTVI was performed as a stand-alone procedure. Procedural success (defined as the device successfully implanted and residual TR ≤2+) was 72.8%. Greater coaptation depth (odds ratio: 24.1; p = 0.002) was an independent predictor of reduced device success. Thirty-day mortality was 3.6% and was significantly lower among patients with procedural success (1.9% vs. 6.9%; p = 0.04); Actuarial survival at 1.5 years was 82.8 ± 4% and was significantly higher among patients who had procedural success achieved.CONCLUSIONS: TTVI is feasible with different technologies, has a reasonable overall procedural success rate, and is associated with low mortality and significant clinical improvement. Mid-term survival is favorable in this high-risk population. Greater coaptation depth is associated with reduced procedural success, which is an independent predictor of mortality.

AB - OBJECTIVES: A large, prospective international registry was developed to evaluate the initial clinical applications of transcatheter tricuspid valve intervention (TTVI) with different devices.BACKGROUND: TTVI for native tricuspid valve dysfunction has been emerging during the last few years as an alternative therapeutic option to serve a large high-risk population of patients with severe symptomatic tricuspid regurgitation (TR).METHODS: The TriValve Registry included 312 high-risk patients with severe TR (76.4 ± 8.5 years of age; 57% female; EuroSCORE II 9 ± 8%) at 18 centers. Interventions included repair at the level of the leaflets (MitraClip, Abbott Vascular, Santa Clara, California; PASCAL Edwards Lifesciences, Irvine, California), annulus (Cardioband, Edwards Lifesciences; TriCinch, 4tech, Galway, Ireland; Trialign, Mitraling, Tewksbury, Massachusetts), or coaptation (FORMA, Edwards Lifesciences) and replacement (Caval Implants, NaviGate, NaviGate Cardiac Structures, Lake Forest, California). Clinical outcomes were prospectively determined during mid-term follow-up.RESULTS: A total of 108 patients (34.6%) had prior left heart valve intervention (84 surgical and 24 transcatheter, respectively). TR etiology was functional in 93%, and mean annular diameter was 46.9 ± 9 mm. In 75% of patients the regurgitant jet was central (vena contracta 1.1 ± 0.5; effective regurgitant orifice area 0.78 ± 0.6 cm2). Pre-procedural systolic pulmonary artery pressure was 41 ± 14.8 mm Hg. Implanted devices included: MitraClip in 210 cases, Trialign in 18 cases, TriCinch first generation in 14 cases, caval valve implantation in 30 cases, FORMA in 24 cases, Cardioband in 13 cases, NaviGate in 6 cases, and PASCAL in 1. In 64% of the cases, TTVI was performed as a stand-alone procedure. Procedural success (defined as the device successfully implanted and residual TR ≤2+) was 72.8%. Greater coaptation depth (odds ratio: 24.1; p = 0.002) was an independent predictor of reduced device success. Thirty-day mortality was 3.6% and was significantly lower among patients with procedural success (1.9% vs. 6.9%; p = 0.04); Actuarial survival at 1.5 years was 82.8 ± 4% and was significantly higher among patients who had procedural success achieved.CONCLUSIONS: TTVI is feasible with different technologies, has a reasonable overall procedural success rate, and is associated with low mortality and significant clinical improvement. Mid-term survival is favorable in this high-risk population. Greater coaptation depth is associated with reduced procedural success, which is an independent predictor of mortality.

KW - Aged

KW - Aged, 80 and over

KW - Cardiac Catheterization/adverse effects

KW - Europe

KW - Female

KW - Heart Valve Prosthesis

KW - Heart Valve Prosthesis Implantation/adverse effects

KW - Humans

KW - Male

KW - North America

KW - Prospective Studies

KW - Prosthesis Design

KW - Recovery of Function

KW - Registries

KW - Severity of Illness Index

KW - Time Factors

KW - Treatment Outcome

KW - Tricuspid Valve/diagnostic imaging

KW - Tricuspid Valve Insufficiency/diagnostic imaging

U2 - 10.1016/j.jcin.2018.10.022

DO - 10.1016/j.jcin.2018.10.022

M3 - SCORING: Journal article

C2 - 30594510

VL - 12

SP - 155

EP - 165

JO - JACC-CARDIOVASC INTE

JF - JACC-CARDIOVASC INTE

SN - 1936-8798

IS - 2

ER -